Hani Raka Karrar, Mahmoud Ismail Nouh, Yousef Ismail Nouh, Mawadah Ismaeel Nouh, Adel S Khan Alhindi, Yousef Hassan Hemeq, Abdullah Mohammed Aljameeli, Jameel Abdullah Aljuaid, Saleh Jabbar Alzahrani, Abdullah Abdulrahman Alsatami, Mona Ali Alkredees, Abdulrahman Olayan Almuqati, Sobhia N Abanmi, Amal Mueidh Alshehri
This systematic review and meta-analysis determine how frequently and how seriously gastrointestinal manifestations affect people with type 2 diabetes mellitus on tirzepatide. Tirzepatide is a recently developed drug that attempts to enhance type 2 diabetics' ability to regulate their blood sugar levels and promote weight reduction. Despite its potential benefits, clinical trials have revealed that the medication may lead to gastrointestinal side effects, including nausea, vomiting, decreased appetite, dyspepsia, constipation, and diarrhea...
September 2023: Curēus